Entries by oslocancer

Registration for Cancer Crosslinks 2015 is open

Cancer Crosslinks 2015 will be held January 15th at The Institute for Cancer Research at the Norwegian Radium Hospital. The program features several renowned international speakers as well as Norwegian experts. Main theme is “Novel insights into tumor heterogeneity and clonal evolution: how to design treatment and follow-up strategies”.   Program and registration form (close […]

Great Kick-off for the Oslo Cancer Cluster Innovation Park

Oslo Cancer Cluster, in collaboration with Radiumhospitalets Legater, invite members and collaborators to the annual Oslo Cancer Cluster R&D Summer Meeting on Wednesday August 20th at the Auditorium , Institute of Cancer Research. Download program and register here The summer meeting will kick off the Oslo Cancer Cluster Innovation Park, and for the first time it […]

Protecting oncology innovations – download presentations

Researchers, clinicians and start-ups filled up the seminar room when Oslo Cancer Cluster Incubator together with the Norwegian Industrial Property Office (Patentstyret) and Inven2 invited to a breakfast meeting on June 18th. The breakfast seminar had a special focus on protecting oncology innovations.

Innovation Norway: Technology Incubator in Asia

Are you aiming for Asian markets? Innovation Norway presents the Tech Incubator Program – TINC TINC in Silicon Valley has created great opportunities for Norwegian tech entrepreneurs and has been fundamental in Innovation Norway’s efforts towards global entrepreneurs. These days the concept is extended to Asian markets with Singapore as the epicenter. Please find more […]

Nordic Nanovector: Betalutin™ granted Orphan Designation in Europe

Oslo Cancer Cluster member Nordic Nanovector`s  lead product candidate Betalutin™ has been granted orphan designation for treatment of follicular lymphoma in Europe by the European Medicines Agency (EMA) and the European Commission (EC). Orphan designation for Betalutin™ will provide the company several advantages, including reduced costs related to the clinical development program, as well as […]

Cambridge-report shows high number of oncology publications per capita in Norway

MBA students from University of Cambridge did a benchmarking of international oncology clusters this spring on behalf of the Oslo Cancer Cluster. Please download an excerpt of the report here. Key findings; • Norway has a high number of oncology publications per capita • The entrepreneurial culture in Norway represents untapped commercial potential • There […]

Targovax successfully completes a 70 MNOK financing

Immunotherapy specialist Targovax announces completion of a 70 MNOK financing, mainly from new investors. The share issue was significantly oversubscribed. CEO Hanne M Kristensen states; “The capital increase of 70 MNOK will make us able to continue developing Targovax’s pipeline of immunotherapies targeting RAS mutated cancer forms, and also gives us a strong position to […]

Vaccibody AS and Phibro Animal Health Corporation enter into Development and License Agreement

The Norwegian vaccine company Vaccibody and Phibro Animal Health Corporation (Nasdaq:PAHC), a global animal health and mineral nutrition company, have signed a global exclusive license agreement which grants Phibro and its affiliates the right to develop, market and sell novel vaccines for the poultry market using the Vaccibody platform technology. Under the agreement, Phibro and […]

Lytix presents at ASCO

Lytix Bioharma presents data at ASCO from the first LTX-315 clinical trial. Sunday June 1st Lytix Biopharma presents results from the first Phase I clinical study with LTX-315 at the 50th annual ASCO (American Society of Clinical Oncology). The results are presented as a poster at the ‘Developmental Therapeutics – Immunotherapy Poster Session’. The poster […]

Pharmaconutrition products for cancer patients

Smartfish is a Norwegian company developing synergistic omega 3 based pharmaconutrition products. Smartfih is now studying the effect of their phamaconutrition on the immune system, and would like to get in contact with Norwegian collaborators. Smartfish joined the Oslo Cancer Cluster in 2014 and currently have two products on the market that have been clinically […]